The primary objective of this phase 2 study is to assess disease-free survival rate of 3 years in patients with NPC. The secondary objective is to observe objective response rate, progression free survival, overall survival and safety
To see the effect if a combination of neoadjuvant chemotherapy combined with Camrelizumab followed by chemoradiotherapy in treating patients without distant metastasis nasopharyngeal carcinoma